Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Review, H2 2017

  • ID: 4432180
  • Report
  • 51 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Astellas Pharma Inc
  • Merck & Co Inc
  • Novartis AG
  • Trellis Bioscience Inc
  • VBI Vaccines Inc
  • Vical Inc
  • MORE
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Review, H2 2017

Summary

Human Cytomegalovirus Envelope Glycoprotein B (gB) pipeline Target constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The latest report Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Review, H2 2017, outlays comprehensive information on the Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Human Cytomegalovirus envelope glycoprotein B plays an important role in host cell entry and cell to cell virus transmission. It is involved in the initial attachment via binding to heparan sulfate together with the gM/gN complex that binds heparin with higher affinity. It interacts with host integrin ITGB1, PDGFRA and EGFR that likely serve as post attachment entry receptors. It participates in the fusion of viral and cellular membranes leading to virus entry into the host cell. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 1, 2, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Infectious Disease, Oncology and Women's Health which include indications Cytomegalovirus (HHV-5) Infections, Female Contraception, Glioblastoma Multiforme (GBM), Gonorrhea, Human Immunodeficiency Virus (HIV) Infections (AIDS), Simplexvirus (HSV) Infections and Trichomonas Vaginitis.

Furthermore, this report also reviews key players involved in Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Human Cytomegalovirus Envelope Glycoprotein B (gB)
  • The report reviews Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Human Cytomegalovirus Envelope Glycoprotein B (gB)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Human Cytomegalovirus Envelope Glycoprotein B (gB) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Astellas Pharma Inc
  • Merck & Co Inc
  • Novartis AG
  • Trellis Bioscience Inc
  • VBI Vaccines Inc
  • Vical Inc
  • MORE
Introduction

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Overview

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Companies Involved in Therapeutics Development

Astellas Pharma Inc

Merck & Co Inc

Novartis AG

Trellis Bioscience Inc

Vakzine Projekt Management GmbH

VBI Vaccines Inc

Vical Inc

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Drug Profiles

ASP-0113 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Monoclonal Antibody to Target CD3 and gB for Cytomegalovirus (HHV-5) Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CSJ-148 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CyMVectin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cytomegalovirus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PPCM - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TRL-345 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VBI-1501A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VBI-1901 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VPM-2001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Dormant Products

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Product Development Milestones

Featured News & Press Releases

Nov 10, 2017: VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at SITC 2017

Oct 11, 2017: VBI Vaccines to Present Phase 1 CMV vaccine data at The World Vaccine Congress Europe 2017 in Barcelona

Oct 10, 2017: Vical Announces Completion of the Phase 3 ASP0113 CMV Vaccine Trial

Aug 28, 2017: VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at The Immuno-Oncology Summit

Aug 15, 2017: VBI Vaccines Announces FDA Acceptance of Investigational New Drug Application for VBI-1901 to Treat Glioblastoma Multiforme

Jul 27, 2017: VBI Vaccines Announces Positive Interim Data from Phase 1 Study of Preventative CMV Vaccine

May 02, 2017: VBI Vaccines Provides Update on its Congenital CMV Phase I Clinical Study

Apr 05, 2017: VBI Vaccines to Present Update on VBI-1901 at the World Vaccine Congress

Nov 10, 2016: VBI Vaccines to Present at the Society of Neuro-Oncology Annual Meeting

Oct 11, 2016: VBI Vaccines Completes Pre-IND Meeting for its Glioblastoma Immunotherapy Candidate

Oct 05, 2016: VBI Vaccines to Present at the World Vaccine Congress Europe

Sep 20, 2016: Vical and Astellas Announce Topline Results from a Phase 2 Study of Investigational Cytomegalovirus Vaccine (ASP0113) in Kidney Transplant Patients

Sep 20, 2016: VBI Vaccines Completes Enrollment of Participants in the Phase I Clinical Trial of its Preventative Cytomegalovirus Vaccine Candidate

Sep 01, 2016: VBI Vaccines to Present at the Vaccine Congress

Aug 29, 2016: VBI Vaccines to Present at the Immuno-Oncology Summit

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indication, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by Astellas Pharma Inc, H2 2017

Pipeline by Merck & Co Inc, H2 2017

Pipeline by Novartis AG, H2 2017

Pipeline by Trellis Bioscience Inc, H2 2017

Pipeline by Vakzine Projekt Management GmbH, H2 2017

Pipeline by VBI Vaccines Inc, H2 2017

Pipeline by Vical Inc, H2 2017

Dormant Projects, H2 2017

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indications, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Astellas Pharma Inc
  • Merck & Co Inc
  • Novartis AG
  • Trellis Bioscience Inc
  • Vakzine Projekt Management GmbH
  • VBI Vaccines Inc
  • Vical Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll